www.fdanews.com/articles/175494-pfizers-breast-cancer-drug-gains-additional-indication
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
Pfizer’s Breast Cancer Drug Gains Additional Indication
February 26, 2016
Pfizer has scooped up an additional indication for Ibrance from the FDA for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer in combination with fulvestrant following endocrine therapy, regardless of menopausal status.
The FDA first approved the drug in February 2015 for the same type of breast cancer in combination with letrozole as initial endocrine-based therapy in postmenopausal women.